About us

CSR

Corporate Social Responsibility

Ability Pharmaceuticals is an innovative and responsible company regarding the relationship with our stakeholders, suppliers, partners, institutions, employees, the environment and society. The objective of our Corporate Social Responsibility is to achieve a sustainable development of the company, understood as a balanced growth in the economic, social and environmental dimensions. At Ability Pharmaceuticals we integrate all of our stakeholders with the commitment to develop cancer medications to improve clinical outcomes through improved efficacy and increased safety.
 
Knowledge sharing and co-development are highly valued at Ability Pharmaceuticals. We work with an extensive network of excellent external partners, from the public and private sectors, with the aim of creating new projects and generating new business opportunities. Ability Pharmaceuticals breaks traditional boundaries between partner companies and promotes the integration of resources and ideas among development groups, organizations and different business units.
 
Ability Pharmaceuticals promotes ethical behavior that builds trust and brings value. That is why the company maintains a responsible, fluid and bidirectional communication with the main interest groups, about the policies, practices and results of our projects. In addition, Ability Pharmaceuticals is committed to respect the ethical codes, carrying out all our activities with professional, ethical and total transparency.
 
We believe that our employees are critical to our social commitment and we are aware that attracting, training and working with tomorrow's leaders and innovators is vital to helping us achieve our business philosophy. That is why Ability Pharmaceuticals supports the training and professional development of all its employees, facilitating family reconciliation and work, as part of the retention strategy of the extraordinary professionals who form the company. Moreover, the company is committed to equal opportunity for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, language or disability.
 
We have a great commitment to the environment, considering fundamental the protection of the field in which our business is developed, since only this way can maintain a sustainable and lasting activity. We promote a healthy and safe work atmosphere for our employees, continually improving to protect the health, safety and welfare of workers.

LATEST NEWS

12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG